641615-41-0

Basic information

• Product Name: 4-(5-bromopyridin-3-yl)-N-(2-methyl-5-nitrophenyl)pyrimidin-2-amine
• Synonyms: 4-(5-bromopyridin-3-yl)-N-(2-methyl-5-nitrophenyl)pyrimidin-2-amine
• CAS NO: 641615-41-0
• Molecular Weight: 386.208
• Mol File: 641615-41-0.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 4-(5-bromopyridin-3-yl)-N-(2-methyl-5-nitrophenyl)pyrimidin-2-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(5-bromopyridin-3-yl)-N-(2-methyl-5-nitrophenyl)pyrimidin-2-amine(641615-41-0)
• EPA Substance Registry System: 4-(5-bromopyridin-3-yl)-N-(2-methyl-5-nitrophenyl)pyrimidin-2-amine(641615-41-0)

Safety Data

• Hazardous Substances Data: 641615-41-0(Hazardous Substances Data)

Upstream product

• 166196-86-7 1-(5-bromopyridin-3-yl)-3-(dimethylamino)prop-2-ene-1-one 
• 152460-07-6 1-(2-methyl-5-nitrophenyl)guanidine 
• 1025717-28-5 (E)-1-(5-bromopyridin-3-yl)-3-(dimethylamino)prop-2-en-1-one 
• 152460-08-7 1-(2-methyl-5-nitrophenyl)guanidine nitrate 
• 38940-62-4 3-acetyl-5-bromopyridine 
• 99-55-8 2-methyl-5-nitroaniline 

Relevant articles and documents

COMPOSITIONS AND METHODS FOR INHIBITING KINASES

The present invention provides methods for the prevention or treatment of Parkinson's Disease using Abelson-family tyrosine kinase inhibitors.

COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS

The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to beat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of c-kit, PDGFRα and PDGFRβ kinases. Formula (I).

AMIDE DERIVATIVE AND MEDICINE

The present invention is directed to an amide derivative having excellent BCR-ABL tyrosine kinase inhibitory activity, or a salt thereof. The present invention provides an amide derivative represented by the following general formula [1]: (wherein R1 represents -CH2-R11, etc.; R2 represents alkyl, halogen, haloalkyl, etc.; R3 represents hydrogen, etc.; Het1 represents a group of the formula [6] as above, etc.; and Het2 represents pyrimidinyl, etc.), or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same as an active ingredient. The compound of the present invention is useful as a BCR-ABL tyrosine kinase inhibitor.